Holen Sie sich die Stockscreener-App
16.54
4.89%
-0.85
Vorhandelsmarkt:
16.66
0.12
+0.73%
Schlusskurs vom Vortag:
$17.39
Offen:
$17.39
24-Stunden-Volumen:
177.59K
Relative Volume:
0.86
Marktkapitalisierung:
$563.91M
Einnahmen:
$99.99M
Nettoeinkommen (Verlust:
$-21.47M
KGV:
-25.07
EPS:
-0.6597
Netto-Cashflow:
$-11.34M
1W Leistung:
-2.25%
1M Leistung:
+0.00%
6M Leistung:
+1.10%
1J Leistung:
+26.16%
1-Tages-Spanne:
$16.46
$17.65
1-Wochen-Bereich:
$16.46
$17.65
52-Wochen-Spanne:
$7.5625
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
16.54 | 592.89M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NPCE Explains How NeuroPace's RNS System Makes Money - MSN
NeuroPace receives FDA approval for AI-driven ECoG Assistant - Investing.com UK
NeuroPace receives FDA approval for AI-driven ECoG Assistant By Investing.com - Investing.com Nigeria
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery Meeting - Investing News Network
NPCENeuropace Inc. stock news, filings & ratings - Quantisnow
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting - Business Wire
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care - Business Wire
NeuroPace Inc (NPCE) CEO covers tax bill through share withholding - Stock Titan
NeuroPace (NPCE) CMO has 358 shares withheld to cover RSU taxes - Stock Titan
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care - Zacks Investment Research
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? - Yahoo Finance Australia
(NPCE) Risk Channels and Responsive Allocation - Stock Traders Daily
NeuroPace (NPCE) Q1 2026 Earnings Transcript - AOL.com
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
NeuroPace (NPCE) CFO receives RSU and stock option awards in Form 4 filing - Stock Titan
NeuroPace (NPCE) CMO receives new RSU and stock option awards - Stock Titan
NeuroPace (NPCE) CEO receives new RSU and stock option awards - Stock Titan
Here's why you should add NeuroPace stock to your portfolio now - MSN
H.C. Wainwright raises NeuroPace stock price target to $20 on guidance - Investing.com Australia
NPCE Maintains by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
First Light, Mathew Arens report ~2.9M NPCE shares (NPCE) - Stock Titan
OrbiMed reports 2,096,527 shares (6.2%) in NeuroPace (NPCE) - Stock Titan
H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
(NPCE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NeuroPace, Inc. (NPCE) reports Q1 loss, tops revenue estimates - MSN
Should You Investigate NeuroPace, Inc. (NASDAQ:NPCE) At US$15.81? - Moomoo
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth - TipRanks
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Earnings Call Highlights RNS Growth Momentum - TipRanks
Neuropace signals $99M-$101M 2026 revenue outlook while targeting 21%-23% underlying RNS growth - MSN
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised - TradingView
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2026 Earnings Call Transcript - Insider Monkey
NeuroPace revenue up 20.1% to USD 22.1M in Q1 2026 - Medical Buyer
NeuroPace, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
NeuroPace Q1 Loss Narrows, Revenue Declines - Moomoo
NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
NeuroPace Q1 2026 Earnings Call Transcript - MarketBeat
Earnings Call Summary | NeuroPace(NPCE.US) Q1 2026 Earnings Conference - Moomoo
NeuroPace Non-GAAP Operating Expenses Outlook Excludes Approximately $10M in Stk-based Compensation, a Non-Cash Expense >NPCE - Moomoo
NeuroPace Q1 Earnings Call Highlights - MarketBeat
NeuroPace Inc revenue rises to 22.1 million as RNS System delivers 20 percent YoY growth - Traders Union
NeuroPace : Investor Presentation - marketscreener.com
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):